文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

阿扎胞苷联合干扰素-α用于异基因外周血干细胞移植后AML/MDS抢先治疗的前瞻性II期研究

Azacitidine combined with interferon-α for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.
PubMed 文献 · Br J Haematol · 2024-07-03

该前瞻性II期研究纳入47例异基因外周血干细胞移植后AML/MDS患者,评估阿扎胞苷联合干扰素-α抢先治疗的有效性与安全性。中位随访1050天,3年总生存率69.5%,无白血病生存率60.4%,无事件生存率35.7%,复发累积发生率36.5%,非复发死亡率4.3%。联合方案耐受良好,未观察到严重骨髓毒性。

要点

  • 47例移植后AML/MDS患者接受阿扎胞苷联合干扰素-α抢先治疗,14例完成计划12个周期。
  • 首次周期后72.3%患者有效,第五周期达峰值77.2%,24例在中位随访1050天内维持持续缓解。
  • 3年总生存率69.5%、无白血病生存率60.4%、无事件生存率35.7%,复发累积发生率36.5%,非复发死亡率4.3%。

核心结论

  • 阿扎胞苷联合干扰素-α作为抢先治疗,对于异基因造血干细胞移植后微小残留病阳性的AML/MDS患者,是安全且有效的预防疾病进展的治疗方法。

研究设计与样本

  • 前瞻性II期临床研究,纳入47例年龄17-62岁的异基因外周血干细胞移植后AML/MDS患者,其中14例完成计划12个周期。

主要发现

  • 首次周期后72.3%患者有效,第五周期达峰值77.2%,24例在中位随访1050天(范围866-1234)内维持持续缓解。
  • 3年总生存率69.5%,无白血病生存率60.4%,无事件生存率35.7%。
  • 复发累积发生率36.5%,非复发死亡率4.3%。
  • 多因素分析显示,接受抢先治疗少于6个周期及干预后无慢性移植物抗宿主病与较差的临床结局显著相关。
  • 联合方案耐受良好,未观察到严重骨髓毒性,大多数不良事件可逆且可控。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This prospective clinical study aimed to evaluate the efficacy and safety of the pre-emptive treatment modality of azacitidine in combination with interferon-α (IFN-α) in AML/MDS patients post-transplantation. Forty-seven patients aged 17-62 were enrolled with 14 patients having completed the planned 12 cycles. Following initiation, 72.3% responded positively after the first cycle, peaking at 77.2% by the fifth cycle. Notably, 24 patients maintained sustained responses throughout a median follow-up of 1050 days (range, 866-1234). Overall survival, leukaemia-free survival and event-free survival probabilities at 3 years were 69.5%, 60.4% and 35.7% respectively. Cumulative incidences of relapse and non-relapse mortality were 36.5% and 4.3% respectively. Multivariate analysis identified that receiving pre-emptive treatment for fewer than six cycles and the absence of chronic graft-versus-host disease after intervention was significantly associated with poorer clinical outcomes. The combination of azacitidine with IFN-α was well-tolerated with no observed severe myelotoxicity, and the majority of adverse events were reversible and manageable. In conclusion, the use of azacitidine in conjunction with IFN-α as pre-emptive therapy is a safe and effective treatment to prevent disease progression in AML/MDS patients with MRD positivity post-allo-HSCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Huang C, Jia Y, Yang J, et al. Azacitidine combined with interferon-α for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study. Br J Haematol. 2024. PMID: 38960381. doi:10.1111/bjh.19628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。